Janssen receives positive CHMP opinion for ERLEADA ™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news